MX360683B - Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico. - Google Patents

Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.

Info

Publication number
MX360683B
MX360683B MX2014002107A MX2014002107A MX360683B MX 360683 B MX360683 B MX 360683B MX 2014002107 A MX2014002107 A MX 2014002107A MX 2014002107 A MX2014002107 A MX 2014002107A MX 360683 B MX360683 B MX 360683B
Authority
MX
Mexico
Prior art keywords
chlorophyll
disorders
treatment
bacterio
photosensitizers
Prior art date
Application number
MX2014002107A
Other languages
English (en)
Spanish (es)
Other versions
MX2014002107A (es
Inventor
Yoram Salomon
Scherz Avigdor
Marcovich Arie
Brandis Alexander
Wagner Daniel
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2014002107A publication Critical patent/MX2014002107A/es
Publication of MX360683B publication Critical patent/MX360683B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014002107A 2011-08-23 2012-08-23 Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico. MX360683B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23
PCT/IL2012/050325 WO2013027222A1 (en) 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Publications (2)

Publication Number Publication Date
MX2014002107A MX2014002107A (es) 2015-04-16
MX360683B true MX360683B (es) 2018-11-13

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002107A MX360683B (es) 2011-08-23 2012-08-23 Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.

Country Status (20)

Country Link
US (4) US9452172B2 (enExample)
EP (1) EP2747763B1 (enExample)
JP (1) JP6215203B2 (enExample)
KR (1) KR101962991B1 (enExample)
CN (1) CN103930108B (enExample)
AU (1) AU2012298156B2 (enExample)
BR (1) BR112014004306A2 (enExample)
CA (1) CA2846011C (enExample)
CL (1) CL2014000432A1 (enExample)
DK (1) DK2747763T3 (enExample)
ES (1) ES2856698T3 (enExample)
HK (1) HK1199412A1 (enExample)
HU (1) HUE053321T2 (enExample)
IN (1) IN2014CN02153A (enExample)
MX (1) MX360683B (enExample)
PE (1) PE20141183A1 (enExample)
PT (1) PT2747763T (enExample)
RU (1) RU2632439C2 (enExample)
WO (1) WO2013027222A1 (enExample)
ZA (1) ZA201402056B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye
EP4335419A3 (en) * 2016-05-05 2024-04-03 David Muller Corneal implant systems and methods
US10849855B2 (en) * 2017-01-03 2020-12-01 Vitrean, Inc. Methods and devices for treating a retinal detachment
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
KR20210093901A (ko) * 2018-10-24 2021-07-28 캘리포니아 인스티튜트 오브 테크놀로지 일중항 산소를 사용한 근시 및 기타 안구 질환의 치료
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
WO2020117974A1 (en) * 2018-12-04 2020-06-11 Avedro, Inc. Compounds and compositions for eye treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
US20040266748A1 (en) * 2001-10-03 2004-12-30 Robinson Byron C Photosensitizing carbamate derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) * 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
KR101502632B1 (ko) 2006-10-24 2015-03-17 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
JPWO2011099602A1 (ja) * 2010-02-12 2013-06-17 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
DK2747763T3 (da) 2021-03-29
ZA201402056B (en) 2015-11-25
BR112014004306A2 (pt) 2017-03-28
JP6215203B2 (ja) 2017-10-18
US20190231874A1 (en) 2019-08-01
US20140378888A1 (en) 2014-12-25
CN103930108B (zh) 2017-05-24
CL2014000432A1 (es) 2014-11-28
RU2632439C2 (ru) 2017-10-04
MX2014002107A (es) 2015-04-16
US20160354468A1 (en) 2016-12-08
AU2012298156A1 (en) 2014-04-10
EP2747763B1 (en) 2020-12-30
HUE053321T2 (hu) 2021-06-28
PT2747763T (pt) 2021-02-22
IN2014CN02153A (enExample) 2015-05-29
KR20140088514A (ko) 2014-07-10
CN103930108A (zh) 2014-07-16
US9452172B2 (en) 2016-09-27
ES2856698T3 (es) 2021-09-28
HK1199412A1 (en) 2015-07-03
JP2014524465A (ja) 2014-09-22
WO2013027222A1 (en) 2013-02-28
US11058772B2 (en) 2021-07-13
KR101962991B1 (ko) 2019-03-27
EP2747763A1 (en) 2014-07-02
CA2846011A1 (en) 2013-02-28
CA2846011C (en) 2019-10-15
US20210330792A1 (en) 2021-10-28
AU2012298156B2 (en) 2017-08-17
PE20141183A1 (es) 2014-10-05
RU2014110784A (ru) 2015-09-27

Similar Documents

Publication Publication Date Title
MX2014002107A (es) Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.
HK1201438A1 (en) Treatment of ocular disease
BR112017024531A2 (pt) lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir)
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
HK1258588A1 (zh) 用於治疗眼科疾病的化合物和制剂
EP2663281A1 (en) Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
HK1205461A1 (zh) 用於眼部传输治疗剂的组合物和方法
MY175318A (en) Androgen composition for treating an opthalmic condition
NZ705624A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
ES2722723T3 (es) Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EA201490845A1 (ru) Улучшенная сшивающая композиция, доставляемая способом ионтофореза, пригодная для лечения кератоконуса
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
NI201000131A (es) Tratamiento para trastornos relacionados con los ojos.
WO2014003850A3 (en) Methods for treatment of ocular diseases
TN2010000368A1 (en) Treatment for ocular-related disorders
RU2011150950A (ru) Способ комплексного лечения рефракционной амблиопии больных миопией высокой степени
UA38111U (ru) Способ предоперационной подготовки пациентов с миопией высокой степени к факоэмульсификации хрусталика с вживлением интраокулярной линзы
UA36913U (uk) Очна мазь для лікування запальних та дистрофічних захворювань переднього відтинку ока

Legal Events

Date Code Title Description
FG Grant or registration